Director/PDMR Shareholding: CEO Share Purchase

Eco Animal Health Group PLC

16 July 2026

 

16 July 2026

ECO Animal Health Group plc

("ECO" or the "Company")

CEO Share Purchase

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that on 16 July 2026 David Hallas, Chief Executive Officer, purchased 22,346 ordinary shares in the Company ("Ordinary Shares") at 89.5 pence per Ordinary Share.

Following this, David Hallas holds 225,387 Ordinary Shares, representing approximately 0.33 per cent. of the Company's issued share capital.

The notification below, provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer) 020 8447 8899 ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Jalini Kalaravy Samed Ethemi 020 7496 3000 Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden 020 3100 2000  Equity Development Hannah Crowe Matt Evans 020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group's proprietary lead product, Aivlosin^® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN^® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in June 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group's website or LinkedIn page for further information.

PDMR Notification

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	David Hallas
2.	Reason for the notification
a.	Position/status	Chief Executive Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP70B55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Purchase of Ordinary Shares
c.	Price(s) and volume(s)	Price(s) Volume(s) 89.5p 22,346
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	16 July 2026
f.	Place of the transaction	XLON - LONDON STOCK EXCHANGE - AIM

 

END